Jump to main content
Jump to site search

Issue 11, 2017
Previous Article Next Article

Boosting the therapeutic efficiency of nanovectors: exocytosis engineering

Author affiliations

Abstract

In this work, we developed a new general strategy, which we named “exocytosis engineering”, to strongly increase the intracellular persistence of nanocarriers and thus the effective dose of transported drugs. The strategy is based on the co-loading of a drug and an exocytosis inhibitor in the nanocarrier, to hinder the high tendency of cells to remove internalized nanocarriers, limiting the pharmacological efficiency of the nanoformulation. In particular, by using a well-known chemotherapeutic drug (doxorubicin) and an efficient exocytosis inhibitor (dimethilamyloride) co-loaded in mesoporous silica nanocarriers, we demonstrated a >6-fold increase in the intracellular dose of the drug (for the same administered dose), achieving a great improvement in its therapeutic action. A strong gain in the cytotoxic effect of the drug was, in fact, observed both in several tumor cell lines and in 3D tumor spheroids. The proposed approach is versatile and broadly applicable to several classes of nanocarriers and drugs, thus opening a fascinating outlook in nanomedicine.

Graphical abstract: Boosting the therapeutic efficiency of nanovectors: exocytosis engineering

Back to tab navigation

Supplementary files

Publication details

The article was received on 16 Jan 2017, accepted on 20 Feb 2017 and first published on 22 Feb 2017


Article type: Communication
DOI: 10.1039/C7NR00364A
Citation: Nanoscale, 2017,9, 3757-3765
  •   Request permissions

    Boosting the therapeutic efficiency of nanovectors: exocytosis engineering

    S. Corvaglia, D. Guarnieri and P. P. Pompa, Nanoscale, 2017, 9, 3757
    DOI: 10.1039/C7NR00364A

Search articles by author

Spotlight

Advertisements